Oral Paclitaxel Reveals Superior Confirmed Response, Survival in Patients With Metastatic Breast Cancer, Compared With IV Paclitaxel

In phase 3 trial results presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, oral paclitaxel with encequidar, the first orally administered paclitaxel, was shown to exhibit superior confirmed response and survival with less neuropathy for patients with metastatic breast cancer compared with intravenous (IV) paclitaxel.

Read the full article here

Related Articles